VRTX

Vertex Pharmaceuticals Incorporated
HealthcareBiotechnologyNASDAQ
$447.54
+$14.45 (3.23%)today
Conviction
0/ 10
Fair Value$547.79
Upside+22.40%
Signal0
Market Cap$111.8B
52W Range$362.50–$510.77
Next EarningsMay 4

Price History

Quick Take

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.

Trailing P/E28.0x
Forward P/E19.6x
P/S9.1x
EPS (TTM)$15.31
Analyst Target$547.79
Analyst Upside22.4%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kMar 1
Conviction: unchanged
VRTX FY2025 10-K: CF Cash Engine + Multi-Product Launch Year

VRTX delivered .0B in FY2025 revenue (+9% YoY), net income .0B (.32 EPS), 86.2% gross margin, 34.8% operating margin, .1B cash, zero long-term debt. CF franchise (~75% patient penetration) remains the...